Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy

Patients with cancer who developed severe, grade 3 or 4 immune-related adverse events (irAEs) during therapy with immune checkpoint inhibitors are at risk for developing severe toxicities again on rechallenge with checkpoint inhibitors. Consequently, medical oncologists and multidisciplinary teams a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Haanen, John, Ernstoff, Marc, Wang, Yinghong, Menzies, Alexander, Puzanov, Igor, Grivas, Petros, Larkin, James, Peters, Solange, Thompson, John, Obeid, Michel
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Commentary
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7295425/
https://ncbi.nlm.nih.gov/pubmed/32532839
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000604
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados